Some studies find that KL-6 were not significantly elevated in some COVID-19 patients with secondary pulmonary fibrosis, possibly because the time when found the occurance of pulmonary fibrosis is later than the time when repair mechanisms was activated and KL-6 was released in large quantities (Xue et al., 2021). This evidence concerns the gene MUC1 and COVID-19.